| Autor: |
Chua, Abigail L., Mehla, Sandhya, Orlova, Yulia Y. |
| Zdroj: |
Current Pain & Headache Reports; Jul2022, Vol. 26 Issue 7, p493-504, 12p |
| Abstrakt: |
Purpose of Review: The aim of this review is to aid in decision-making when choosing safe and effective options for preventive migraine medications. Recent Findings: In Part 2, we have compiled clinically relevant safety considerations for commonly used migraine prophylactic treatments. Preventive treatment of episodic migraine includes nonspecific and migraine-specific drugs. While medications from several pharmacological classes–such as anticonvulsants, beta-blockers, and antidepressants–have an established efficacy in migraine prevention, they are associated with a number of side effects. The safety of migraine-specific treatments such as anti-CGRP monoclonal antibodies and gepants are also discussed. Summary: This review highlights safety concerns of commonly used migraine prophylactic agents and offers suggestions on how to mitigate those risks. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink